Accenture Collaborates with 1910 Genetics to Help Biopharma Companies Transform Drug Discovery with AI
Accenture (NYSE:
ACN) has invested, through Accenture Ventures, in 1910 Genetics (or “1910”), a biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. As part of this investment, Accenture and 1910 will collaborate to combine tailored solutions and scalable infrastructure to help clients in the biopharma industry accelerate drug target identification, reduce costs, and deliver better, more affordable therapies to patients.
1910 Genetics Launches CANDID-CNS™, an AI Model for Blood-Brain Barrier Permeability Prediction that Outperforms the Industry Standard
1910 Genetics (or “1910”), the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, today announced the launch of CANDID-CNS™, an attentive graph neural network for predicting the blood-brain barrier (BBB) permeability and distribution of small molecule drug candidates designed to treat diseases of the central nervous system (CNS).
Microsoft and 1910 Genetics Partner to Build the Infrastructure Layer for Drug Discovery and Development Using AI and High-Performance Computing
1910 Genetics (or “1910”), the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, today announced a new five-year commercial agreement and go-to-market collaboration with Microsoft to harness advanced artificial intelligence (AI) and next-generation, high-performance computing (HPC) to reverse 70 years of declining pharmaceutical R&D productivity.
1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director
1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors. Gandhi joins as an independent board director and will provide a critical clinical perspective alongside his extensive background in biotechnology investing and strategic collaboration at a time when 1910 Genetics continues to build pharmaceutical and technology partnerships and advance its own pipeline of AI-derived therapeutics.
1910 Genetics Appoints Bridget Cole to Chief Scientific Officer
1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Bridget Cole to Chief Scientific Officer. Cole, who previously served as SVP and Head of Chemistry, will lead the biotech’s scientific research operations, set and advance research priorities, and work closely with 1910’s AI leadership to guide model and platform development with her drug development expertise.
1910 Genetics Appoints Patrick Genestin as Chief Business Officer
1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to accelerate the design of small molecule and protein therapeutics, today announced that it has appointed Patrick Genestin as Chief Business Officer. Genestin will lead strategic business development partnerships with biotech and pharmaceutical companies to leverage 1910’s AI-driven drug discovery platforms across all stages of preclinical drug discovery and in all major therapeutic areas.
1910 Genetics Appoints Desney Tan from Microsoft to Board of Directors
1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, today announced that it has appointed Desney Tan, Vice President and Managing Director of Microsoft Health Futures, to the company’s Board of Directors. With experience in artificial intelligence, machine learning and genomics, Tan brings the board a unique perspective on the benefits and opportunities of combining biomedical technologies with life sciences.
1910 Genetics Appoints Dr. Jennifer Leeds as Independent Board Director
1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, today announced that Jennifer Leeds, Ph.D., will join as an independent member of the company’s Board of Directors. With two decades in the pharmaceutical sector, Dr. Leeds joins 1910 Genetics with extensive experience in drug discovery and development, including strategic partnerships and evaluation of novel targets, platforms and technologies.
1910 Genetics Announces Grand Opening of its First Dedicated Laboratory and Office Facility in Boston’s Seaport District
1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, today announced that the company has opened its new headquarters in Boston’s Seaport District, building dedicated laboratory and office facilities. The new location will allow 1910 Genetics to accommodate its growing leadership and scientific teams, and advance its multi-module drug platforms for the discovery of new classes of small molecule and protein therapeutics. The company was previously located at the LabCentral incubator in Cambridge, Massachusetts.
1910 Genetics Receives NIH Phase I STTR Grant for Discovery of Novel Non-Opioid Drugs for Chronic Pain
1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, has been awarded a ~$550,000 Phase I STTR grant by the National Institutes of Health (NIH). The grant, received from the National Institute of Neurological Disorders and Stroke (NINDS) as part of the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, supports the discovery of a novel small molecule drug that is safe and effective at blocking the protein product of a non-opioid gene for the treatment of chronic pain.
